| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.36 | 0.05 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.21 | 0.05 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.06 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.063 | 0.06 |